Compare Sana Biotechnology Inc (SANA) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Value Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $2.81 (market cap $836.71M), while Vanguard Value Index Fund ETF trades at $220.46 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 313.6× Sana Biotechnology Inc's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| SANA | VTV | |
|---|---|---|
Market Cap | $836.71M | $262.40B |
Volume | 4,507,444 | 3,293,281 |
Sector | Health | — |
52-Week High | $5.92 | $227.51 |
52-Week Low | $2.68 | $182.86 |
Typical Hold Time | 23 Days | 142 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
VTV trades at $220.55, up 1.07% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital Management and Blue Edge Capital. Recent news highlights value stocks outperforming growth in 2026, with VTV's 2.3% yield and low 0.03% fee attracting income-focused investors amid market rotation from tech.
The outlook remains mixed—technical indicators suggest near-term pressure, but strong institutional interest and value stock momentum support long-term stability. Key risks include underperformance versus broad market indices and sensitivity to interest rate changes. The dividend yield provides income cushion, yet investors should weigh VTV's value tilt against broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
